These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

170 related items for PubMed ID: 17875515

  • 1. The predictive value of EGFR and HER-2/neu in tumor tissue and serum for response to anthracycline-based neoadjuvant chemotherapy of breast cancer.
    Schippinger W, Dandachi N, Regitnig P, Hofmann G, Balic M, Neumann R, Samonigg H, Bauernhofer T.
    Am J Clin Pathol; 2007 Oct; 128(4):630-7. PubMed ID: 17875515
    [Abstract] [Full Text] [Related]

  • 2. Evaluation of HER-2/neu amplification and other biological markers as predictors of response to neoadjuvant anthracycline-based chemotherapy in primary breast cancer: the role of anthracycline dose intensity.
    Bozzetti C, Musolino A, Camisa R, Bisagni G, Flora M, Bassano C, Martella E, Lagrasta C, Nizzoli R, Personeni N, Leonardi F, Cocconi G, Ardizzoni A.
    Am J Clin Oncol; 2006 Apr; 29(2):171-7. PubMed ID: 16601438
    [Abstract] [Full Text] [Related]

  • 3. Serum EGFR and serum HER-2/neu are useful predictive and prognostic markers in metastatic breast cancer patients treated with metronomic chemotherapy.
    Sandri MT, Johansson HA, Zorzino L, Salvatici M, Passerini R, Maisonneuve P, Rocca A, Peruzzotti G, Colleoni M.
    Cancer; 2007 Aug 01; 110(3):509-17. PubMed ID: 17559147
    [Abstract] [Full Text] [Related]

  • 4. Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401.
    Scandinavian Breast Group Trial 9401Laboratory of Cancer Biology, Institute of Medical Technology, and Department of Oncology, Tampere University and Tampere University Hospital, Tampere, Finland., Tanner M, Isola J, Wiklund T, Erikstein B, Kellokumpu-Lehtinen P, Malmström P, Wilking N, Nilsson J, Bergh J.
    J Clin Oncol; 2006 Jun 01; 24(16):2428-36. PubMed ID: 16682728
    [Abstract] [Full Text] [Related]

  • 5. Topoisomerase IIalpha gene status and prediction of pathological complete remission after anthracycline-based neoadjuvant chemotherapy in endocrine non-responsive Her2/neu-positive breast cancer.
    Orlando L, Del Curto B, Gandini S, Ghisini R, Pietri E, Torrisi R, Balduzzi A, Cardillo A, Dellapasqua S, Veronesi P, Viale G, Goldhirsch A, Colleoni M.
    Breast; 2008 Oct 01; 17(5):506-11. PubMed ID: 18456496
    [Abstract] [Full Text] [Related]

  • 6. Epidermal growth factor receptor expression correlates with poor survival in patients who have breast carcinoma treated with doxorubicin-based neoadjuvant chemotherapy.
    Buchholz TA, Tu X, Ang KK, Esteva FJ, Kuerer HM, Pusztai L, Cristofanilli M, Singletary SE, Hortobagyi GN, Sahin AA.
    Cancer; 2005 Aug 15; 104(4):676-81. PubMed ID: 15981280
    [Abstract] [Full Text] [Related]

  • 7. Relationship between hormonal receptors, HER-2, p53 protein, Bcl-2, and MIB-1 status and the antitumor effects of neoadjuvant anthracycline-based chemotherapy in invasive breast cancer patients.
    Kariya S, Ogawa Y, Nishioka A, Moriki T, Ohnishi T, Ito S, Murata Y, Yoshida S.
    Radiat Med; 2005 May 15; 23(3):189-94. PubMed ID: 15940066
    [Abstract] [Full Text] [Related]

  • 8. Predictive biological markers for response of invasive breast cancer to anthracycline/cyclophosphamide-based primary (radio-)chemotherapy.
    Prisack HB, Karreman C, Modlich O, Audretsch W, Danae M, Rezai M, Bojar H.
    Anticancer Res; 2005 May 15; 25(6C):4615-21. PubMed ID: 16334152
    [Abstract] [Full Text] [Related]

  • 9. Prognostic and predictive impact of the HER-2/ neu extracellular domain (ECD) in the serum of patients treated with chemotherapy for metastatic breast cancer.
    Müller V, Witzel I, Lück HJ, Köhler G, von Minckwitz G, Möbus V, Sattler D, Wilczak W, Löning T, Jänicke F, Pantel K, Thomssen C.
    Breast Cancer Res Treat; 2004 Jul 15; 86(1):9-18. PubMed ID: 15218357
    [Abstract] [Full Text] [Related]

  • 10. Biological markers as predictive factors of response to neoadjuvant taxanes and anthracycline chemotherapy in breast carcinoma.
    Zhou B, Yang DQ, Xie F.
    Chin Med J (Engl); 2008 Mar 05; 121(5):387-91. PubMed ID: 18364105
    [Abstract] [Full Text] [Related]

  • 11. EGFR activity in HER-2 over-expressing metastatic breast cancer: evidence for simultaneous phosphorylation of Her-2/neu and EGFR.
    Gschwantler-Kaulich D, Hudelist G, Koestler WJ, Czerwenka K, Mueller R, Helmy S, Ruecklinger E, Kubista E, Singer CF.
    Oncol Rep; 2005 Aug 05; 14(2):305-11. PubMed ID: 16012707
    [Abstract] [Full Text] [Related]

  • 12. Intracellular coexpression of epidermal growth factor receptor, Her-2/neu, and p21ras in human breast cancers: evidence for the existence of distinctive patterns of genetic evolution that are common to tumors from different patients.
    Shackney SE, Pollice AA, Smith CA, Janocko LE, Sweeney L, Brown KA, Singh SG, Gu L, Yakulis R, Lucke JF.
    Clin Cancer Res; 1998 Apr 05; 4(4):913-28. PubMed ID: 9563885
    [Abstract] [Full Text] [Related]

  • 13. HER-2/neu expression as a predictor of response to neoadjuvant docetaxel in patients with operable breast carcinoma.
    Learn PA, Yeh IT, McNutt M, Chisholm GB, Pollock BH, Rousseau DL, Sharkey FE, Cruz AB, Kahlenberg MS.
    Cancer; 2005 Jun 01; 103(11):2252-60. PubMed ID: 15834928
    [Abstract] [Full Text] [Related]

  • 14. Changes of topoisomerase IIalpha expression in breast tumors after neoadjuvant chemotherapy predicts relapse-free survival.
    Tinari N, Lattanzio R, Natoli C, Cianchetti E, Angelucci D, Ricevuto E, Ficorella C, Marchetti P, Alberti S, Piantelli M, Iacobelli S.
    Clin Cancer Res; 2006 Mar 01; 12(5):1501-6. PubMed ID: 16533774
    [Abstract] [Full Text] [Related]

  • 15. Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy.
    Johnston S, Trudeau M, Kaufman B, Boussen H, Blackwell K, LoRusso P, Lombardi DP, Ben Ahmed S, Citrin DL, DeSilvio ML, Harris J, Westlund RE, Salazar V, Zaks TZ, Spector NL.
    J Clin Oncol; 2008 Mar 01; 26(7):1066-72. PubMed ID: 18212337
    [Abstract] [Full Text] [Related]

  • 16. Prognostic and predictive impact of soluble epidermal growth factor receptor (sEGFR) protein in the serum of patients treated with chemotherapy for metastatic breast cancer.
    Müller V, Witzel I, Pantel K, Krenkel S, Lück HJ, Neumann R, Keller T, Dittmer J, Jänicke F, Thomssen C.
    Anticancer Res; 2006 Mar 01; 26(2B):1479-87. PubMed ID: 16619561
    [Abstract] [Full Text] [Related]

  • 17. Kinetics of serum HER-2/neu changes in patients with HER-2-positive primary breast cancer after initiation of primary chemotherapy.
    Mazouni C, Hall A, Broglio K, Fritsche H, Andre F, Esteva FJ, Hortobagyi GN, Buzdar AU, Pusztai L, Cristofanilli M.
    Cancer; 2007 Feb 01; 109(3):496-501. PubMed ID: 17149760
    [Abstract] [Full Text] [Related]

  • 18. The prognostic and predictive value of immunohistochemically detected HER-2/neu overexpression in 361 patients with ovarian cancer: a multicenter study.
    Riener EK, Arnold N, Kommoss F, Lauinger S, Pfisterer J.
    Gynecol Oncol; 2004 Oct 01; 95(1):89-94. PubMed ID: 15385115
    [Abstract] [Full Text] [Related]

  • 19. Serum epidermal growth factor receptor/HER-2 predicts poor survival in patients with metastatic breast cancer.
    Souder C, Leitzel K, Ali SM, Demers L, Evans DB, Chaudri-Ross HA, Hackl W, Hamer P, Carney W, Lipton A.
    Cancer; 2006 Nov 15; 107(10):2337-45. PubMed ID: 17048231
    [Abstract] [Full Text] [Related]

  • 20. Assessment of histologic features and expression of biomarkers in predicting pathologic response to anthracycline-based neoadjuvant chemotherapy in patients with breast carcinoma.
    Wang J, Buchholz TA, Middleton LP, Allred DC, Tucker SL, Kuerer HM, Esteva FJ, Hortobagyi GN, Sahin AA.
    Cancer; 2002 Jun 15; 94(12):3107-14. PubMed ID: 12115341
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.